

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

|                       |                                      |
|-----------------------|--------------------------------------|
| <b>Name of entity</b> | <b>ARGENICA THERAPEUTICS LIMITED</b> |
| <b>ABN</b>            | <b>38 620 388 230</b>                |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

|                            |               |
|----------------------------|---------------|
| <b>Name of Director</b>    | LIZ DALLIMORE |
| <b>Date of last notice</b> | 8 AUGUST 2024 |

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

|   |  |
|---|--|
| <b>Direct or indirect interest</b>  | INDIRECT   |
| <b>Nature of indirect interest<br/>(including registered holder)</b><br><small>Note: Provide details of the circumstances giving rise to the relevant interest.</small> | TRUSTEE AND BENEFICIARY  |
| <b>Date of change</b>   | 3 JUNE 2025  |
| <b>No. of securities held prior to change</b>   | MRS ELIZABETH JANE DAWSON + MR<br>LEWIS MACDONALD DAWSON<br><DAWSON FAMILY A/C><br><br>1,640,909 – ORDINARY SHARES<br><br>2,000,000 – UNLISTED OPTIONS,<br>EXERCISE PRICE \$0.65, EXPIRY DATE<br>03 JUN 2025 |
| <b>Class</b>  | ORDINARY SHARES & UNLISTED<br>OPTIONS  |

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

|  |   |
|--|---|
| <b>Number acquired</b>   | 352,345 – ORDINARY SHARES   |
| <b>Number disposed</b>   | 352,345 – OPTIONS EXERCISED<br>1,647,655 – OPTIONS CANCELLED IN LIEU OF PAYING OPTION EXERCISE PROCEEDS   |
| <b>Value/Consideration</b><br><small>Note: If consideration is non-cash, provide details and estimated valuation</small>   | Terms of options include a cashless exercise mechanism. 1,647,655 options have been cancelled equal to the value of exercise proceeds due (\$1,300,000) using the 15 day VWAP of \$0.789 at notice of exercise. |
| <b>No. of securities held after change</b>   | MRS ELIZABETH JANE DAWSON + MR LEWIS MACDONALD DAWSON<br><DAWSON FAMILY A/C><br><br>1,993,254 – ORDINARY SHARES   |
| <b>Nature of change</b><br><small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small> | EXERCISE OF OPTIONS   |

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

|   |     |
|---|-----|
| <b>Detail of contract</b>   | N/A |
| <b>Nature of interest</b>   | N/A |
| <b>Name of registered holder (if issued securities)</b>   | N/A |
| <b>Date of change</b>   | N/A |
| <b>No. and class of securities to which interest related prior to change</b><br><small>Note: Details are only required for a contract in relation to which the interest has changed</small> | N/A |
| <b>Interest acquired</b>  | N/A |
| <b>Interest disposed</b>  | N/A |

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

|   |     |
|---|-----|
| <b>Value/Consideration</b><br><small>Note: If consideration is non-cash, provide details and an estimated valuation</small> | N/A |
| <b>Interest after change</b>  | N/A |

**Part 3 – <sup>+</sup>Closed period**

|   |     |
|---|-----|
| <b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b> | NO  |
| <b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>  | N/A |
| <b>If prior written clearance was provided, on what date was this provided?</b>   | N/A |

---

<sup>+</sup> See chapter 19 for defined terms.